Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurélien Robert

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Revue De Synthese|January 28, 2014
[Human nature and the complexion of the body as seen by Italian physicians at the end of the middle ages]Joël Chandelier, Aurélien Robert
Revue De Synthese|January 28, 2014
[Not Available]Joël Chandelier, Aurélien Robert
Revue De Synthese|January 28, 2014
[Not Available]Aurélien Robert, Joël Chandelier, Laetitia Loviconi, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03Olivier Trédan, Delphine Loirat, Sylvie Chabaud, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Revue De Synthese|January 28, 2014
[Human nature and the complexion of the body as seen by Italian physicians at the end of the middle ages]Joël Chandelier, Aurélien Robert
Revue De Synthese|January 28, 2014
[Not Available]Joël Chandelier, Aurélien Robert
Revue De Synthese|January 28, 2014
[Not Available]Aurélien Robert, Joël Chandelier, Laetitia Loviconi, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03Olivier Trédan, Delphine Loirat, Sylvie Chabaud, et al.
Pageof 1